# Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

> **NCT04123366** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 300 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Olaparib
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04123366
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-18
- **Primary completion:** 2026-06-29
- **Final completion:** 2026-06-29
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04123366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04123366, "Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04123366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*